{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T06:23:17Z","timestamp":1795069397408,"version":"4.10.2"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"DOI":"10.1186\/s12933-025-02607-w","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T09:33:08Z","timestamp":1738920788000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["The role of glucagon-like peptide-1 receptor (GLP-1R) agonists in enhancing endothelial function: a potential avenue for improving heart failure with preserved ejection fraction (HFpEF)"],"prefix":"10.1186","volume":"24","author":[{"given":"Darshan","family":"Hullon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghasaq K.","family":"Subeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yelizaveta","family":"Volkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Janiec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Trach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruslan","family":"Mnevets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,7]]},"reference":[{"issue":"10","key":"2607_CR1","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1016\/j.cardfail.2023.07.006","volume":"29","author":"B Bozkurt","year":"2023","unstructured":"Bozkurt B, Ahmad T, Alexander KM, Baker WL, Bosak K, Breathett K, et al. Heart failure epidemiology and outcomes statistics: a report of the heart failure society of America. J Card Fail. 2023;29(10):1412\u201351.","journal-title":"J Card Fail"},{"key":"2607_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-020-01349-3","author":"DM Adamczak","year":"2020","unstructured":"Adamczak DM, Oduah MT, Kiebalo T, Nartowicz S, B\u0119ben M, Pochylski M, Ciep\u0142ucha A, Gwizda\u0142a A, Lesiak M, Straburzy\u0144ska-Migaj E. Heart failure with preserved ejection fraction\u2014a concise review. Curr Cardiol Rep. 2020. https:\/\/doi.org\/10.1007\/s11886-020-01349-3.","journal-title":"Curr Cardiol Rep"},{"key":"2607_CR3","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1007\/s00059-022-05124-8","volume":"47","author":"FR Heinzel","year":"2022","unstructured":"Heinzel FR, Shah SJ. The future of heart failure with preserved ejection fraction. Herz. 2022;47:308\u201323. https:\/\/doi.org\/10.1007\/s00059-022-05124-8.","journal-title":"Herz"},{"key":"2607_CR4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052256","author":"TE Owan","year":"2006","unstructured":"Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. NEJM. 2006. https:\/\/doi.org\/10.1056\/NEJMoa052256.","journal-title":"NEJM"},{"issue":"2","key":"2607_CR5","doi-asserted-by":"publisher","first-page":"794","DOI":"10.3390\/ijms25020794","volume":"25","author":"L Stoicescu","year":"2024","unstructured":"Stoicescu L, Crisan D, Morgovan C, Avram L, Ghibu S. Heart failure with preserved ejection fraction: the pathophysiological mechanisms behind the clinical phenotypes and the therapeutic approach. Int J Mol Sci. 2024;25(2):794.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2607_CR6","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s12872-016-0418-9","volume":"16","author":"TB Abebe","year":"2016","unstructured":"Abebe TB, Gebreyohannes EA, Tefera YG, Abegaz TM. Patients with HFpEF and HFrEF have different clinical characteristics but similar prognosis: a retrospective cohort study. BMC Cardiovasc Disord. 2016;16(1):232.","journal-title":"BMC Cardiovasc Disord"},{"key":"2607_CR7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107038","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, B\u00f6hm M, Brunner-La Rocca HP, Choi DJ, Chopra V, Chuquiure-Valenzuela E, Giannetti N. Empagliflozin in heart failure with a preserved ejection fraction. NEJM. 2021. https:\/\/doi.org\/10.1056\/NEJMoa2107038.","journal-title":"NEJM"},{"issue":"12","key":"2607_CR8","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089\u201398.","journal-title":"N Engl J Med"},{"key":"2607_CR9","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1161\/CIRCULATIONAHA.123.067505","volume":"149","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod MN, Verma S, Borlaug BA, Butler J, Davies MJ, Jon Jensen T, Rasmussen S, Erlang Marstrand P, Petrie MC, Shah SJ, Ito H. Effects of semaglutide on symptoms, function, and quality of life in patients with heart failure with preserved ejection fraction and obesity: a prespecified analysis of the STEP-HFpEF trial. Circulation. 2024;149:204\u201316. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.067505.","journal-title":"Circulation"},{"key":"2607_CR10","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1097\/HCO.0000000000001117","volume":"39","author":"F Capone","year":"2024","unstructured":"Capone F, Nambiar N, Schiattarella GG. Beyond weight loss: the emerging role of incretin-based treatments in cardiometabolic HFpEF. Curr Opin Cardiol. 2024;39:148\u201353.","journal-title":"Curr Opin Cardiol"},{"issue":"4","key":"2607_CR11","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","volume":"62","author":"WJ Paulus","year":"2013","unstructured":"Paulus WJ, Tsch\u00f6pe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62(4):263\u201371.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2607_CR12","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1152\/physrev.00017.2002","volume":"83","author":"DL Brutsaert","year":"2003","unstructured":"Brutsaert DL. Cardiac endothelial-myocardial signaling: its role in cardiac growth, contractile performance, and rhythmicity. Physiol Rev. 2003;83(1):59\u2013115.","journal-title":"Physiol Rev"},{"issue":"12","key":"2607_CR13","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1161\/01.CIR.100.12.1338","volume":"100","author":"XL Qi","year":"1999","unstructured":"Qi XL, Stewart DJ, Gosselin H, Azad A, Picard P, Andries L, et al. Improvement of endocardial and vascular endothelial function on myocardial performance by captopril treatment in postinfarct rat hearts. Circulation. 1999;100(12):1338\u201345.","journal-title":"Circulation"},{"key":"2607_CR14","unstructured":"Hemodynamic stresses induce endothelial dysfunction and remodeling of pulmonary artery in experimental compensated heart failure\u2014PubMed. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/10851216\/"},{"issue":"4","key":"2607_CR15","first-page":"352","volume":"16","author":"GX Chu","year":"1995","unstructured":"Chu GX, Ling Q, Guo ZG. Effects of endocardial endothelium in myocardial mechanics of hypertrophied myocardium of rats. Zhongguo Yao Li Xue Bao. 1995;16(4):352\u20136.","journal-title":"Zhongguo Yao Li Xue Bao"},{"key":"2607_CR16","unstructured":"The pathomorphological alterations of endocardial endothelium in experimental diabetes and diabetes associated with hyperlipidemia\u2014PubMed [cited 2024 Jul 24]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/8777284\/"},{"issue":"6","key":"2607_CR17","doi-asserted-by":"publisher","first-page":"e003806","DOI":"10.1161\/CIRCHEARTFAILURE.116.003806","volume":"10","author":"AB Gevaert","year":"2017","unstructured":"Gevaert AB, Shakeri H, Leloup AJ, Van Hove CE, De Meyer GR, Vrints CJ, et al. Endothelial senescence contributes to heart failure with preserved ejection fraction in an aging mouse model. Circ Heart Fail. 2017;10(6):e003806.","journal-title":"Circ Heart Fail"},{"issue":"18","key":"2607_CR18","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1016\/j.jacc.2012.08.004","volume":"60","author":"CSP Lam","year":"2012","unstructured":"Lam CSP, Brutsaert DL. Endothelial dysfunction. J Am Coll Cardiol. 2012;60(18):1787\u20139.","journal-title":"J Am Coll Cardiol"},{"key":"2607_CR19","unstructured":"Impaired endothelium-dependent regulation of ventricular relaxation in pressure-overload cardiac hypertrophy\u2014PubMed [cited 2024 Jul 24]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/10769288\/"},{"key":"2607_CR20","unstructured":"Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota\u2014PubMed. [cited 2024 Jul 24]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/17404159\/"},{"key":"2607_CR21","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.jacc.2008.11.051","volume":"53","author":"CS Lam","year":"2008","unstructured":"Lam CS, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redfield MM. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol. 2008;53:1119\u201326. https:\/\/doi.org\/10.1016\/j.jacc.2008.11.051.","journal-title":"J Am Coll Cardiol"},{"key":"2607_CR22","doi-asserted-by":"crossref","unstructured":"McEniery CM, Wallace S, Mackenzie IS, McDonnell B, Yasmin null, Newby DE, et al. Endothelial function is associated with pulse pressure, pulse wave velocity, and augmentation index in healthy humans. Hypertens Dallas Tex 1979. 2006;48(4):602\u20138.","DOI":"10.1161\/01.HYP.0000239206.64270.5f"},{"key":"2607_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.07.036","author":"E Akiyama","year":"2012","unstructured":"Akiyama E, Sugiyama S, Matsuzawa Y, Konishi M, Suzuki H, Nozaki T, Ohba K, Matsubara J, Maeda H, Horibata Y, Sakamoto K. Incremental prognostic significance of peripheral endothelial dysfunction in patients with heart failure with normal left ventricular ejection fraction. J Am Coll Cardiol. 2012. https:\/\/doi.org\/10.1016\/j.jacc.2012.07.036.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"2607_CR24","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/micc.12223","volume":"22","author":"V Sucato","year":"1994","unstructured":"Sucato V, Evola S, Novo G, Sansone A, Quagliana A, Andolina G, et al. Angiographic evaluation of coronary microvascular dysfunction in patients with heart failure and preserved ejection fraction. Microcirc N Y N. 1994;22(7):528\u201333.","journal-title":"Microcirc N Y N"},{"key":"2607_CR25","unstructured":"Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. PubMed. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/25552356\/"},{"key":"2607_CR26","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000155615.68924.B3","author":"C Tschope","year":"2005","unstructured":"Tschope C, Bock CT, Kasner M, Noutsias M, Westermann D, Schwimmbeck PL, Pauschinger M, Poller WC, Kuhl U, Kandolf R, Schultheiss HP. High prevalence of cardiac parvovirus B19 infection in patients with isolated left ventricular diastolic dysfunction. Circulation. 2005. https:\/\/doi.org\/10.1161\/01.CIR.0000155615.68924.B3.","journal-title":"Circulation"},{"key":"2607_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.03.077","author":"BA Borlaug","year":"2010","unstructured":"Borlaug BA, Olson TP, Lam CS, Flood KS, Lerman A, Johnson BD, Redfield MM. Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2010. https:\/\/doi.org\/10.1016\/j.jacc.2010.03.077.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"2607_CR28","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1001\/jamacardio.2021.1825","volume":"6","author":"CJ Rush","year":"2021","unstructured":"Rush CJ, Berry C, Oldroyd KG, Rocchiccioli JP, Lindsay MM, Touyz RM, et al. Prevalence of coronary artery disease and coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction. JAMA Cardiol. 2021;6(10):1130\u201343.","journal-title":"JAMA Cardiol"},{"key":"2607_CR29","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s10741-023-10362-x","volume":"29","author":"X Lin","year":"2023","unstructured":"Lin X, Wu G, Wang S, Huang J. The prevalence of coronary microvascular dysfunction (CMD) in heart failure with preserved ejection fraction (HFpEF): a systematic review and meta-analysis. Heart Fail Rev. 2023;29:405\u201316.","journal-title":"Heart Fail Rev"},{"issue":"6","key":"2607_CR30","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.cmet.2013.04.008","volume":"17","author":"JE Campbell","year":"2013","unstructured":"Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013;17(6):819\u201337.","journal-title":"Cell Metab"},{"issue":"16","key":"2607_CR31","doi-asserted-by":"publisher","first-page":"4822","DOI":"10.3390\/molecules26164822","volume":"26","author":"J Berndt","year":"2021","unstructured":"Berndt J, Ooi SL, Pak SC. What is the mechanism driving the reduction of cardiovascular events from glucagon-like peptide-1 receptor agonists?-A mini review. Molecules. 2021;26(16):4822.","journal-title":"Molecules"},{"issue":"7","key":"2607_CR32","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1210\/endo.137.7.8770921","volume":"137","author":"BP Bullock","year":"1996","unstructured":"Bullock BP, Heller RS, Habener JF. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology. 1996;137(7):2968\u201378.","journal-title":"Endocrinology"},{"issue":"2","key":"2607_CR33","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1210\/endrev\/bnaa032","volume":"42","author":"BA McLean","year":"2020","unstructured":"McLean BA, Wong CK, Campbell JE, Hodson DJ, Trapp S, Drucker DJ. Revisiting the complexity of GLP-1 action from sites of synthesis to receptor activation. Endocr Rev. 2020;42(2):101\u201332.","journal-title":"Endocr Rev"},{"key":"2607_CR34","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1111\/apt.18244","volume":"60","author":"A Fatima","year":"2024","unstructured":"Fatima A, Maryam A, Nadeem MS, Asmat KN. GLP-1 receptor agonists: a new frontier in combating metabolic liver disease complications. Aliment Pharmacol Ther. 2024;60:1499\u2013500.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"2607_CR35","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jchf.2018.10.007","volume":"7","author":"A Xanthopoulos","year":"2019","unstructured":"Xanthopoulos A, Starling RC, Kitai T, Triposkiadis F. Heart failure and liver disease: cardiohepatic interactions. JACC Heart Fail. 2019;7(2):87\u201397.","journal-title":"JACC Heart Fail"},{"issue":"4","key":"2607_CR36","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1007\/s11897-023-00613-1","volume":"20","author":"RM Inciardi","year":"2023","unstructured":"Inciardi RM, Mantovani A, Targher G. Non-alcoholic fatty liver disease as an emerging risk factor for heart failure. Curr Heart Fail Rep. 2023;20(4):308\u201319.","journal-title":"Curr Heart Fail Rep"},{"issue":"5","key":"2607_CR37","doi-asserted-by":"publisher","first-page":"4517","DOI":"10.1007\/s11357-024-01153-9","volume":"46","author":"D Kucsera","year":"2024","unstructured":"Kucsera D, Ruppert M, Sayour NV, T\u00f3th VE, Kov\u00e1cs T, Heged\u0171s ZI, et al. NASH triggers cardiometabolic HFpEF in aging mice. GeroScience. 2024;46(5):4517\u201331.","journal-title":"GeroScience"},{"issue":"7","key":"2607_CR38","doi-asserted-by":"publisher","first-page":"101970","DOI":"10.1016\/j.clinre.2022.101970","volume":"46","author":"Y Zafar","year":"2022","unstructured":"Zafar Y, Rashid AM, Siddiqi AK, Ellahi A, Ahmed A, Hussain H, et al. Effect of novel glucose lowering agents on non-alcoholic fatty liver disease: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2022;46(7):101970.","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"8","key":"2607_CR39","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s11906-023-01242-8","volume":"25","author":"OO Badmus","year":"2023","unstructured":"Badmus OO, Hinds TD, Stec DE. Mechanisms linking metabolic-associated fatty liver disease (MAFLD) to cardiovascular disease. Curr Hypertens Rep. 2023;25(8):151\u201362.","journal-title":"Curr Hypertens Rep"},{"issue":"6","key":"2607_CR40","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1177\/08971900241253661","volume":"37","author":"M Wood","year":"2024","unstructured":"Wood M, Kennedy AG, Khan S, Hitt JR, Davis K, Reddy SS, et al. Impact of GLP-1 receptor agonist use in patients with steatotic liver disease and type 2 diabetes: a retrospective cohort study. J Pharm Pract. 2024;37(6):1297\u2013302.","journal-title":"J Pharm Pract"},{"key":"2607_CR41","volume":"16","author":"F Kanwal","year":"2024","unstructured":"Kanwal F, Kramer JR, Li L, Yang YX, Cao Y, Yu X, et al. GLP-1 receptor agonists and risk for cirrhosis and related complications in patients with metabolic dysfunction-associated steatotic liver disease. JAMA Intern Med. 2024;16: e244661.","journal-title":"JAMA Intern Med"},{"issue":"2","key":"2607_CR42","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.jacc.2021.11.007","volume":"79","author":"A Mantovani","year":"2022","unstructured":"Mantovani A, Byrne CD, Benfari G, Bonapace S, Simon TG, Targher G. Risk of heart failure in patients with nonalcoholic fatty liver disease: JACC review topic of the week. J Am Coll Cardiol. 2022;79(2):180\u201391.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"2607_CR43","doi-asserted-by":"publisher","first-page":"1120085","DOI":"10.3389\/fcvm.2022.1120085","volume":"12","author":"Z Yang","year":"2023","unstructured":"Yang Z, Tian R, Zhang XJ, Cai J, She ZG, Li H. Effects of treatment of non-alcoholic fatty liver disease on heart failure with preserved ejection fraction. Front Cardiovasc Med. 2023;12(9):1120085.","journal-title":"Front Cardiovasc Med"},{"issue":"7","key":"2607_CR44","doi-asserted-by":"publisher","first-page":"328","DOI":"10.4330\/wjc.v15.i7.328","volume":"15","author":"J Arriola-Montenegro","year":"2023","unstructured":"Arriola-Montenegro J, Beas R, Cerna-Viacava R, Chaponan-Lavalle A, Hernandez Randich K, Chambergo-Michilot D, et al. Therapies for patients with coexisting heart failure with reduced ejection fraction and non-alcoholic fatty liver disease. World J Cardiol. 2023;15(7):328\u201341.","journal-title":"World J Cardiol"},{"issue":"8","key":"2607_CR45","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3390\/diseases12080186","volume":"12","author":"AI Gad","year":"2024","unstructured":"Gad AI, Ibrahim NF, Almadani N, Mahfouz R, Nofal HA, El-Rafey DS, et al. Therapeutic effects of semaglutide on nonalcoholic fatty liver disease with type 2 diabetes mellitus and obesity: an open-label controlled trial. Diseases. 2024;12(8):186.","journal-title":"Diseases"},{"issue":"8","key":"2607_CR46","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1161\/CIRCULATIONAHA.121.055459","volume":"145","author":"AM Shaman","year":"2022","unstructured":"Shaman AM, Bain SC, Bakris GL, Buse JB, Idorn T, Mahaffey KW, et al. Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER. Circulation. 2022;145(8):575\u201385.","journal-title":"Circulation"},{"key":"2607_CR47","unstructured":"Taal MW, Selby NM. Glucagon-like peptide-1 receptor agonists: new evidence of kidney and cardiovascular protection from the FLOW and SELECT Trials. Am J Kidney Dis. 2024. Available from: https:\/\/www.ajkd.org\/article\/S0272-6386(24)00975-2\/fulltext"},{"issue":"1","key":"2607_CR48","doi-asserted-by":"publisher","first-page":"e14330","DOI":"10.1111\/eci.14330","volume":"55","author":"M Kanbay","year":"2025","unstructured":"Kanbay M, Copur S, Guldan M, Ozbek L, Mallamaci F, Zoccali C. Glucagon and glucagon-like peptide-1 dual agonist therapy: a possible future towards fatty kidney disease. Eur J Clin Invest. 2025;55(1):e14330.","journal-title":"Eur J Clin Invest"},{"issue":"11","key":"2607_CR49","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1136\/thorax-2023-221040","volume":"79","author":"FS Yen","year":"2024","unstructured":"Yen FS, Hsu CC, Wei JCC, Tsai FJ, Huang Y, Yu TS, et al. Glucagon-like peptide-1 receptor agonists may benefit cardiopulmonary outcomes in patients with COPD. Thorax. 2024;79(11):1017\u201323.","journal-title":"Thorax"},{"issue":"6","key":"2607_CR50","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.2337\/dc20-1794","volume":"44","author":"Y Albogami","year":"2021","unstructured":"Albogami Y, Cusi K, Daniels MJ, Wei YJJ, Winterstein AG. Glucagon-like peptide 1 receptor agonists and chronic lower respiratory disease exacerbations among patients with type 2 diabetes. Diabetes Care. 2021;44(6):1344\u201352.","journal-title":"Diabetes Care"},{"key":"2607_CR51","doi-asserted-by":"publisher","first-page":"129","DOI":"10.2147\/COPD.S393323","volume":"18","author":"W Wang","year":"2023","unstructured":"Wang W, Mei A, Qian H, Li D, Xu H, Chen J, et al. The role of glucagon-like peptide-1 receptor agonists in chronic obstructive pulmonary disease. Int J Chronic Obstr Pulm Dis. 2023;18:129\u201337.","journal-title":"Int J Chronic Obstr Pulm Dis"},{"key":"2607_CR52","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-024-04033-6","author":"K Kantreva","year":"2024","unstructured":"Kantreva K, Katsaounou P, Saltiki K, Trakada G, Ntali G, Stratigou T, et al. The possible effect of anti-diabetic agents GLP-1RA and SGLT-2i on the respiratory system function. Endocrine. 2024. https:\/\/doi.org\/10.1007\/s12020-024-04033-6.","journal-title":"Endocrine"},{"issue":"1","key":"2607_CR53","doi-asserted-by":"publisher","first-page":"18091","DOI":"10.1038\/s41598-020-74912-1","volume":"10","author":"J Fandi\u00f1o","year":"2020","unstructured":"Fandi\u00f1o J, Toba L, Gonz\u00e1lez-Mat\u00edas LC, Diz-Chaves Y, Mallo F. GLP-1 receptor agonist ameliorates experimental lung fibrosis. Sci Rep. 2020;10(1):18091.","journal-title":"Sci Rep"},{"issue":"12","key":"2607_CR54","doi-asserted-by":"publisher","first-page":"4503","DOI":"10.1210\/en.2013-1666","volume":"154","author":"NE Viby","year":"2013","unstructured":"Viby NE, Isidor MS, Buggeskov KB, Poulsen SS, Hansen JB, Kissow H. Glucagon-like peptide-1 (GLP-1) reduces mortality and improves lung function in a model of experimental obstructive lung disease in female mice. Endocrinology. 2013;154(12):4503\u201311.","journal-title":"Endocrinology"},{"issue":"1","key":"2607_CR55","doi-asserted-by":"publisher","first-page":"034","DOI":"10.1210\/jendso\/bvz034","volume":"4","author":"E Balk-M\u00f8ller","year":"2020","unstructured":"Balk-M\u00f8ller E, Windel\u00f8v JA, Svendsen B, Hunt J, Ghiasi SM, S\u00f8rensen CM, et al. Glucagon-like peptide 1 and atrial natriuretic peptide in a female mouse model of obstructive pulmonary disease. J Endocr Soc. 2020;4(1):034.","journal-title":"J Endocr Soc."},{"issue":"1","key":"2607_CR56","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s11154-012-9229-1","volume":"14","author":"R Muniyappa","year":"2013","unstructured":"Muniyappa R, Sowers JR. Role of insulin resistance in endothelial dysfunction. Rev Endocr Metab Disord. 2013;14(1):5\u201312.","journal-title":"Rev Endocr Metab Disord"},{"issue":"13","key":"2607_CR57","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.2174\/1381612811319130010","volume":"19","author":"S Del Turco","year":"2013","unstructured":"Del Turco S, Gaggini M, Daniele G, Basta G, Folli F, Sicari R, et al. Insulin resistance and endothelial dysfunction: a mutual relationship in cardiometabolic risk. Curr Pharm Des. 2013;19(13):2420\u201331.","journal-title":"Curr Pharm Des"},{"issue":"11","key":"2607_CR58","doi-asserted-by":"publisher","first-page":"E947","DOI":"10.1152\/ajpendo.00400.2015","volume":"310","author":"R Wei","year":"2016","unstructured":"Wei R, Ma S, Wang C, Ke J, Yang J, Li W, et al. Exenatide exerts direct protective effects on endothelial cells through the AMPK\/Akt\/eNOS pathway in a GLP-1 receptor-dependent manner. Am J Physiol Endocrinol Metab. 2016;310(11):E947-957.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"3","key":"2607_CR59","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1007\/s13300-018-0435-z","volume":"9","author":"Y Hu","year":"2018","unstructured":"Hu Y, Liu J, Wang G, Xu Y. The effects of exenatide and metformin on endothelial function in newly diagnosed type 2 diabetes mellitus patients: a case-control study. Diabetes Ther. 2018;9(3):1295\u2013305.","journal-title":"Diabetes Ther"},{"issue":"4","key":"2607_CR60","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1177\/1479164113481817","volume":"10","author":"T Gaspari","year":"2013","unstructured":"Gaspari T, Welungoda I, Widdop RE, Simpson RW, Dear AE. The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE\u2212\/\u2212 mouse model. Diabetes Vasc Dis Res. 2013;10(4):353\u201360.","journal-title":"Diabetes Vasc Dis Res"},{"issue":"1","key":"2607_CR61","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1677\/JOE-08-0468","volume":"201","author":"H Liu","year":"2009","unstructured":"Liu H, Dear AE, Knudsen LB, Simpson RW. A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules. J Endocrinol. 2009;201(1):59\u201366.","journal-title":"J Endocrinol"},{"key":"2607_CR62","doi-asserted-by":"publisher","first-page":"e002","DOI":"10.1621\/nrs.04002","volume":"4","author":"MA Maxwell","year":"2006","unstructured":"Maxwell MA, Muscat GEO. The NR4A subgroup: immediate early response genes with pleiotropic physiological roles. Nucl Recept Signal. 2006;4:e002.","journal-title":"Nucl Recept Signal"},{"issue":"3","key":"2607_CR63","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.diabres.2014.09.046","volume":"106","author":"E Gurkan","year":"2014","unstructured":"Gurkan E, Tarkun I, Sahin T, Cetinarslan B, Canturk Z. Evaluation of exenatide versus insulin glargine for the impact on endothelial functions and cardiovascular risk markers. Diabetes Res Clin Pract. 2014;106(3):567\u201375.","journal-title":"Diabetes Res Clin Pract"},{"key":"2607_CR64","unstructured":"Preventive effects of exenatide on endothelial dysfunction induced by ischemia-reperfusion injury via KATP channels\u2014PubMed. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/22155457\/"},{"issue":"6","key":"2607_CR65","doi-asserted-by":"publisher","first-page":"589","DOI":"10.3390\/cells8060589","volume":"8","author":"TH Tsai","year":"2019","unstructured":"Tsai TH, Lee CH, Cheng CI, Fang YN, Chung SY, Chen SM, et al. Liraglutide inhibits endothelial-to-mesenchymal transition and attenuates neointima formation after endovascular injury in streptozotocin-induced diabetic mice. Cells. 2019;8(6):589.","journal-title":"Cells"},{"issue":"671","key":"2607_CR66","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.abb.2019.07.008","volume":"15","author":"X Luo","year":"2019","unstructured":"Luo X, Hu Y, He S, Ye Q, Lv Z, Liu J, et al. Dulaglutide inhibits high glucose- induced endothelial dysfunction and NLRP3 inflammasome activation. Arch Biochem Biophys. 2019;15(671):203\u20139.","journal-title":"Arch Biochem Biophys"},{"issue":"2","key":"2607_CR67","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.bbrc.2014.07.136","volume":"451","author":"H Onuma","year":"2014","unstructured":"Onuma H, Inukai K, Kitahara A, Moriya R, Nishida S, Tanaka T, et al. The glucagon-like peptide 1 receptor agonist enhances intrinsic peroxisome proliferator-activated receptor \u03b3 activity in endothelial cells. Biochem Biophys Res Commun. 2014;451(2):339\u201344.","journal-title":"Biochem Biophys Res Commun"},{"key":"2607_CR68","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.molimm.2019.09.021","volume":"116","author":"W Chang","year":"2019","unstructured":"Chang W, Zhu F, Zheng H, Zhou Z, Miao P, Zhao L, et al. Glucagon-like peptide-1 receptor agonist dulaglutide prevents ox-LDL-induced adhesion of monocytes to human endothelial cells: An implication in the treatment of atherosclerosis. Mol Immunol. 2019;116:73\u20139.","journal-title":"Mol Immunol"},{"issue":"11","key":"2607_CR69","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1161\/ATVBAHA.107.149179","volume":"27","author":"E Galkina","year":"2007","unstructured":"Galkina E, Ley K. Vascular adhesion molecules in atherosclerosis. Arterioscler Thromb Vasc Biol. 2007;27(11):2292\u2013301.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"10","key":"2607_CR70","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1172\/JCI11871","volume":"107","author":"MI Cybulsky","year":"2001","unstructured":"Cybulsky MI, Iiyama K, Li H, Zhu S, Chen M, Iiyama M, et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest. 2001;107(10):1255\u201362.","journal-title":"J Clin Invest"},{"issue":"8","key":"2607_CR71","doi-asserted-by":"publisher","first-page":"e2925","DOI":"10.1002\/dmrr.2925","volume":"33","author":"P Di Tomo","year":"2017","unstructured":"Di Tomo P, Lanuti P, Di Pietro N, Baldassarre MPA, Marchisio M, Pandolfi A, et al. Liraglutide mitigates TNF-\u03b1 induced pro-atherogenic changes and microvesicle release in HUVEC from diabetic women. Diabetes Metab Res Rev. 2017;33(8):e2925.","journal-title":"Diabetes Metab Res Rev"},{"issue":"4","key":"2607_CR72","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.2337\/db09-1694","volume":"59","author":"M Arakawa","year":"2010","unstructured":"Arakawa M, Mita T, Azuma K, Ebato C, Goto H, Nomiyama T, et al. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes. 2010;59(4):1030\u20137.","journal-title":"Diabetes"},{"issue":"9","key":"2607_CR73","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1002\/iub.2046","volume":"71","author":"W Yue","year":"2019","unstructured":"Yue W, Li Y, Ou D, Yang Q. The GLP-1 receptor agonist liraglutide protects against oxidized LDL-induced endothelial inflammation and dysfunction via KLF2. IUBMB Life. 2019;71(9):1347\u201354.","journal-title":"IUBMB Life"},{"key":"2607_CR74","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.athplu.2022.05.004","volume":"49","author":"DM Jensen","year":"2022","unstructured":"Jensen DM, Skovsted GF, Bonde MFB, Bentzon JF, Rolin B, Franck G, et al. Semaglutide treatment attenuates vessel remodelling in ApoE-\/- mice following vascular injury and blood flow perturbation. Atheroscler Plus. 2022;49:32\u201341.","journal-title":"Atheroscler Plus"},{"issue":"1","key":"2607_CR75","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1159\/000381097","volume":"52","author":"L Eriksson","year":"2015","unstructured":"Eriksson L, Saxelin R, R\u00f6hl S, Roy J, Caidahl K, Nystr\u00f6m T, et al. Glucagon-like peptide-1 receptor activation does not affect re-endothelialization but reduces intimal hyperplasia via direct effects on smooth muscle cells in a nondiabetic model of arterial injury. J Vasc Res. 2015;52(1):41\u201352.","journal-title":"J Vasc Res"},{"issue":"1","key":"2607_CR76","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.bbrc.2010.12.131","volume":"405","author":"H Goto","year":"2011","unstructured":"Goto H, Nomiyama T, Mita T, Yasunari E, Azuma K, Komiya K, et al. Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces intimal thickening after vascular injury. Biochem Biophys Res Commun. 2011;405(1):79\u201384.","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"2607_CR77","first-page":"275","volume":"24","author":"G Concei\u00e7\u00e3o","year":"2016","unstructured":"Concei\u00e7\u00e3o G, Heinonen I, Louren\u00e7o AP, Duncker DJ, Falc\u00e3o-Pires I. Animal models of heart failure with preserved ejection fraction. Neth Heart J Mon J Neth Soc Cardiol Neth Heart Found. 2016;24(4):275\u201386.","journal-title":"Neth Heart J Mon J Neth Soc Cardiol Neth Heart Found"},{"issue":"6","key":"2607_CR78","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.jacbts.2017.07.013","volume":"2","author":"M Valero-Mu\u00f1oz","year":"2017","unstructured":"Valero-Mu\u00f1oz M, Backman W, Sam F. Murine models of heart failure with preserved ejection fraction: a \u201cfishing expedition.\u201d JACC Basic Transl Sci. 2017;2(6):770\u201389.","journal-title":"JACC Basic Transl Sci"},{"issue":"1","key":"2607_CR79","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1161\/atv.0000615456.97862.30","volume":"40","author":"J Helmstadter","year":"2020","unstructured":"Helmstadter J, Frenis K, Filippou K, Grill A, Dib M, Kalinovic S, et al. Endothelial GLP-1 (Glucagon-Like Peptide-1) receptor mediates cardiovascular protection by liraglutide in mice with experimental arterial hypertension. Arterioscler Thromb Vasc Biol. 2020;40(1):145\u201358.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2607_CR80","doi-asserted-by":"crossref","unstructured":"Rutledge C, Enriquez A, Redding K, Lopez M, Mullett S, Gelhaus SL, et al. Liraglutide protects against diastolic dysfunction and improves ventricular protein translation. Cardiovasc Drugs Ther. 2023.","DOI":"10.1101\/2022.08.23.504997"},{"issue":"927","key":"2607_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2022.175048","volume":"15","author":"TE Banks","year":"2022","unstructured":"Banks TE, Rajapaksha M, Zhang LH, Bai F, Wang NP, Zhao ZQ. Suppression of angiotensin II-activated NOX4\/NADPH oxidase and mitochondrial dysfunction by preserving glucagon-like peptide-1 attenuates myocardial fibrosis and hypertension. Eur J Pharmacol. 2022;15(927): 175048.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"2607_CR82","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1161\/CIRCULATIONAHA.112.091215","volume":"127","author":"MH Noyan-Ashraf","year":"2013","unstructured":"Noyan-Ashraf MH, Shikatani EA, Schuiki I, Mukovozov I, Wu J, Li RK, et al. A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity. Circulation. 2013;127(1):74\u201385.","journal-title":"Circulation"},{"issue":"2","key":"2607_CR83","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s13105-022-00939-9","volume":"79","author":"A Durak","year":"2023","unstructured":"Durak A, Turan B. Liraglutide provides cardioprotection through the recovery of mitochondrial dysfunction and oxidative stress in aging hearts. J Physiol Biochem. 2023;79(2):297\u2013311.","journal-title":"J Physiol Biochem"},{"issue":"9","key":"2607_CR84","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1093\/cvr\/cvaa256","volume":"117","author":"C Withaar","year":"2021","unstructured":"Withaar C, Meems LMG, Markousis-Mavrogenis G, Boogerd CJ, Sillje HHW, Schouten EM, et al. The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction. Cardiovasc Res. 2021;117(9):2108\u201324.","journal-title":"Cardiovasc Res"},{"issue":"1","key":"2607_CR85","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1177\/1479164112449562","volume":"10","author":"C Irace","year":"2013","unstructured":"Irace C, De Luca S, Shehaj E, Carallo C, Loprete A, Scavelli F, et al. Exenatide improves endothelial function assessed by flow mediated dilation technique in subjects with type 2 diabetes: results from an observational research. Diabetes Vasc Dis Res. 2013;10(1):72\u20137.","journal-title":"Diabetes Vasc Dis Res"},{"issue":"7","key":"2607_CR86","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.2337\/db14-0976","volume":"64","author":"J Koska","year":"2015","unstructured":"Koska J, Sands M, Burciu C, D\u2019Souza KM, Raravikar K, Liu J, et al. Exenatide Protects against glucose- and lipid-induced endothelial dysfunction: evidence for direct vasodilation effect of GLP-1 receptor agonists in humans. Diabetes. 2015;64(7):2624\u201335.","journal-title":"Diabetes"},{"issue":"5","key":"2607_CR87","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1007\/s10741-020-09936-w","volume":"26","author":"S Ida","year":"2021","unstructured":"Ida S, Kaneko R, Imataka K, Okubo K, Shirakura Y, Azuma K, et al. Effects of oral antidiabetic drugs and glucagon-like peptide-1 receptor agonists on left ventricular diastolic function in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. Heart Fail Rev. 2021;26(5):1151\u20138.","journal-title":"Heart Fail Rev"},{"issue":"1","key":"2607_CR88","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.clinthera.2022.12.006","volume":"45","author":"L Huixing","year":"2023","unstructured":"Huixing L, Di F, Daoquan P. Effect of glucagon-like peptide-1 receptor agonists on prognosis of heart failure and cardiac function: a systematic review and meta-analysis of randomized controlled trials. Clin Ther. 2023;45(1):17\u201330.","journal-title":"Clin Ther"},{"key":"2607_CR89","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s10557-022-07360-w","volume":"38","author":"SY Wong","year":"2022","unstructured":"Wong SY, Lee A, Sia AHJ, Wo YJ, Teo YH, Teo YN, et al. Effects of glucagon-like peptide-1 receptor agonist (GLP-1RA) on cardiac structure and function: a systematic review and meta-analysis of randomized-controlled trials. Cardiovasc Drugs Ther. 2022;38:371\u201389.","journal-title":"Cardiovasc Drugs Ther"},{"key":"2607_CR90","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1111\/dom.15557","volume":"26","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Yang D, Jia Q, Yan J, An F. The effect of glucagon-like peptide-1 receptor agonists on cardiac function and structure in patients with or without type 2 diabetes mellitus: an updated systematic review and meta-analysis. Diabetes Obes Metab. 2024;26:2401\u201311. https:\/\/doi.org\/10.1111\/dom.15557.","journal-title":"Diabetes Obes Metab"},{"key":"2607_CR91","doi-asserted-by":"publisher","first-page":"8838026","DOI":"10.1155\/2021\/8838026","volume":"2021","author":"K Yagi","year":"2021","unstructured":"Yagi K, Imamura T, Tada H, Chujo D, Liu J, Shima Y, et al. Diastolic cardiac function improvement by liraglutide is mainly body weight reduction dependent but independently contributes to B-type natriuretic peptide reduction in patients with type 2 diabetes with preserved ejection fraction. J Diabetes Res. 2021;2021:8838026.","journal-title":"J Diabetes Res"},{"issue":"1","key":"2607_CR92","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12933-019-0857-6","volume":"18","author":"MB Bizino","year":"2019","unstructured":"Bizino MB, Jazet IM, Westenberg JJM, van Eyk HJ, Paiman EHM, Smit JWA, et al. Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial. Cardiovasc Diabetol. 2019;18(1):55.","journal-title":"Cardiovasc Diabetol"},{"issue":"Supplement_1","key":"2607_CR93","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1093\/eurheartjsupp\/suae011","volume":"26","author":"PL Temporelli","year":"2024","unstructured":"Temporelli PL. Role of glucagon-like peptide-1 agonists in obesity and heart failure with preserved ejection fraction. Eur Heart J Suppl. 2024;26(Supplement_1):127\u2013530.","journal-title":"Eur Heart J Suppl."},{"issue":"1","key":"2607_CR94","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1210\/clinem\/dgad398","volume":"109","author":"JP Ferreira","year":"2023","unstructured":"Ferreira JP, Sharma A, Butler J, Packer M, Zannad F, Vasques-N\u00f3voa F, et al. Glucagon-like peptide-1 receptor agonists across the spectrum of heart failure. J Clin Endocrinol Metab. 2023;109(1):4\u20139.","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02607-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-025-02607-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02607-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T09:33:22Z","timestamp":1738920802000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-025-02607-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,7]]},"references-count":94,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2607"],"URL":"https:\/\/doi.org\/10.1186\/s12933-025-02607-w","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,7]]},"assertion":[{"value":"11 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. Our study is a review and does not involve patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"70"}}